nach oben

Drugs in R&D

Erschienen in:

01.01.2003 | Adis R&D Profile

Testosterone-Buccal — Columbia

COL 1621, Striant, Testosterone PHBT, Testosterone Progressive Hydration Buccal Tablet

Erschienen in: Drugs in R&D | Ausgabe 1/2003

Einloggen, um Zugang zu erhalten

Excerpt

Columbia Laboratories is developing a buccal testosterone tablet [COL 1621, Striant™] using its Progressive Hydration technology.¹ The testosterone Progressive Hydration Buccal Tablet (PHBT) is intended for sustained delivery of testosterone as hormonal replacement in hypogonadal men. A phase II trial of testosterone PHBT in 66 patients has been completed in two European countries. Preliminary results from an ongoing phase III trial conducted in the US has also been reported. …

This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

Columbia Laboratories. Columbia Laboratories Announces European Marketing Partnership With Ardana Bioscience for Testosterone Buccal Bioadhesive Product. Media Release: 16 Oct 2002. Available from URL: http://www.businesswire.com

Drewe J, Levine H, Larsen F, Mair S. Pharmacokinetics of a new testosterone formulation, COL-1621, for hormonal replacement in males. Results of a single dose study in healthy females. 82nd Annual Meeting of the Endocrine Society: abstr. 2350, 21 Jun 2000

Columbia Laboratories Inc. Columbia Laboratories announces successful results from phase III comparative trial for testosterone buccal tablet. Media Release: [2 pages], 12 Nov 2001. Available from URL: http://www.columbialabs.com

Wang C, Kipnes M, Matsumoto A, Dobs AS, Cunningham G, et al. Novel testosterone bioadhesive buccal tablet — pharmacokinetics and safety evaluation. 84th Annual Meeting of the Endocrine Society: 471, 19 Jun 2002. Harbor-UCLA Medical Center and Research and Education Institute, Torrance, California, USA

Korbonitis M, Cullen D, Ross RRJ, Stalla G, Reincke M, et al. A comparison of Col-1621, a novel testosterone bioadhesive buccal tablet, with Androderm in hypogonadal males. 84th Annual Meeting of the Endocrine Society: 472, 19 Jun 2002. St Bartholomew’s Hospital, London, England

Columbia Laboratories Inc. Positive Data On Columbia Labs’ Testosterone Buccal Product Presented At Endocrine Society Meeting Media Release: 20 Jun 2002. Available from URL: http://www.businesswire.com

Titel: Testosterone-Buccal — Columbia
COL 1621, Striant, Testosterone PHBT, Testosterone Progressive Hydration Buccal Tablet
Publikationsdatum: 01.01.2003
Verlag: Springer International Publishing
Erschienen in: Drugs in R&D / Ausgabe 1/2003
Print ISSN: 1174-5886
Elektronische ISSN: 1179-6901
DOI: https://doi.org/10.2165/00126839-200304010-00015

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2003

Sitafloxacin

Selegiline-Transdermal — Somerset

Effect of Policosanol on Carbon Tetrachloride-Induced Acute Liver Damage in Sprague-Dawley Rats

Profile Summary

Trabectedin

Immunosuppressive and Anti-Inflammatory Mechanisms of Triptolide, the Principal Active Diterpenoid from the Chinese Medicinal Herb Tripterygium wilfordii Hook. f.